Advancing the Diagnostic-to-Treatment Continuum in Gastrointestinal & Genitourinary Cancer Care – New York

New York will bring together leading experts from across gastrointestinal and genitourinary oncology, pathology, molecular diagnostics, and translational science for a multidisciplinary conference focused on the advances redefining precision cancer care across GI and GU malignancies.

The program is chaired by Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center, a gastrointestinal medical oncologist and internationally recognized clinical investigator whose work has helped advance biomarker-driven treatment and innovative immunotherapy approaches in colorectal and gastrointestinal cancers.

Reflecting the rapidly evolving landscape of GI and GU cancer care, the conference will explore how emerging biomarkers, molecular and genomic profiling, evolving disease biology, and novel therapies are changing the diagnosis, classification, and treatment of cancers across the gastrointestinal and genitourinary spectrum.

Through expert presentations, case-based education, and multidisciplinary panel discussions, participants will examine important developments in colorectal, pancreatic, gastric and gastroesophageal, hepatobiliary, prostate, renal, bladder, and other GI and GU malignancies, while exploring the expanding role of precision diagnostics in treatment selection and patient management.

Key areas of focus will include targeted therapies, immunotherapy, molecular and genomic testing, biomarker-guided treatment strategies, liquid biopsy, ctDNA, emerging diagnostic technologies, treatment resistance, and novel therapeutic approaches –  with an emphasis on translating rapidly evolving science into meaningful clinical decisions.

By bringing together specialists across diagnosis, molecular characterization, and treatment, the New York conference creates a collaborative environment for examining the full diagnostic-to-treatment continuum and the innovations shaping the future of GI and GU cancer care.

This version makes the GI/GU focus much clearer while still keeping the broader precision oncology feel you use across the series.